
Spruce Biosciences Reports Positive FDA Meetings and Advances TA-ERT BLA Submission for Q4 2026
Spruce Biosciences Advances Toward 2026 BLA Submission for Tralesinidase Alfa in Sanfilippo Syndrome Type B Spruce Biosciences, Inc., a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies for neurological disorders with significant unmet medical needs, has announced important…












